The GLP-1 Dilemma: How Employers Can Control Costs Without Losing Talent
GLP-1 medications like Ozempic and Wegovy are changing the employee benefits landscape. While these treatments may support long-term health outcomes, they are also driving significant increases in pharmacy costs for employer-sponsored health plans.
For benefits managers, the challenge is balancing employee expectations with long-term plan sustainability.
Today’s workforce increasingly views coverage for GLP-1 medications as part of a competitive benefits package. At the same time, employers are navigating rising specialty drug costs, evolving healthcare strategies, and growing pressure to manage budgets responsibly.
Forward-thinking organizations are moving beyond the simple question of whether to cover these medications. Instead, they are focusing on smarter plan design strategies, including:
- Clinical eligibility requirements
- Wellness program integration
- Pharmacy benefit optimization
- Cost-sharing models
- Employee education and communication
Clear communication is especially important. Employees want to understand what is covered, how benefits work, and what support resources are available to them.
The growing demand for GLP-1 medications reflects a larger shift toward more personalized and strategic employee benefits planning.
At Edelman Wealth Management, we help businesses design employee benefits strategies that balance cost control, employee wellbeing, and long-term organizational goals.
#uncomplicatedadvice #unparalleledservice #openenrollment #enrollment #healthinsurance #healthcoverage #employeebenefits #healthplan